Blog
RSS FeedPosted by Michael Wonder on 03 Jun 2016
NICE publishes appraisal consultation for pirfenidone (Esbriet) for patients with idiopathic pulmonary fibrosis
3 June 2016 - NICE has published an appraisal consultation document for pirfenidone (Esbriet) for use by patients with idiopathic ...
Posted by Michael Wonder on 03 Jun 2016
FDA approves first blood test to detect gene mutation associated with non-small cell lung cancer
1 June 2016 - The U.S. FDA today approved the cobas EGFR Mutation Test v2, a blood-based companion diagnostic for the ...
Posted by Michael Wonder on 02 Jun 2016
Cobimetinib in advanced melanoma with BRAF V600 mutation: added benefit now considerable
2 June 2016 - New analyses from the commenting procedure showed further advantages of the drug. ...
Posted by Michael Wonder on 02 Jun 2016
FDA approves new diagnostic imaging agent to detect rare neuroendocrine tumours
1 June 2016 - The U.S. FDA today approved Netspot, the first kit for the preparation of gallium Ga 68 dotatate ...
Posted by Michael Wonder on 02 Jun 2016
Novartis drug Afinitor receives EU approval to treat certain types of advanced gastro-intestinal and lung neuroendocrine tumours
2 June 2016 - Afinitor fills critical need in EU as first approved therapy for advanced, progressive, non-functional lung neuroendocrine tumour ...
Posted by Michael Wonder on 02 Jun 2016
TGA approves lesinurad (Zurampic)
2 June 2016 - The TGA has approved Astra Zeneca's lesinurad (Zurampic). ...
Posted by Michael Wonder on 01 Jun 2016
European Commission approves Trevicta (paliperidone palmitate a 3-monthly injection), for maintenance treatment of schizophrenia
31 May 2016 - Trevicta is the first treatment for schizophrenia to be administered four times a year. ...
Posted by Michael Wonder on 01 Jun 2016
U.S. FDA approves once-daily Jentadueto XR (linagliptin and metformin hydrochloride extended release tablets) for adults with type 2 diabetes
31 May 2016 - The US FDA has approved Jentadueto XR (linagliptin and metformin hydrochloride extended release tablets) for the treatment ...
Posted by Michael Wonder on 01 Jun 2016
Ramucirumab in colorectal and lung cancer: some additional benefits, some reductions in benefits
1 June 2016 - Germany's IQWiG has just completed its assessment of Lilly's Cyramza for patients with colorectal cancer or ...
Posted by Michael Wonder on 01 Jun 2016
NICE asks company to put leukaemia drug forward for new Cancer Drugs Fund
1 June 2016 - NICE has published a second appraisal consultation document for ibrutinib for chronic lymphocytic leukaemia. ...
Posted by Michael Wonder on 01 Jun 2016
TGA approves new indication for Perjeta
1 June 2016 - The TGA has approved a new use for Roche's Perjeta (pertuzumab). ...
Posted by Michael Wonder on 31 May 2016
Allergan receives FDA approval of Teflaro (ceftaroline fosamil acetate monohydrate) for paediatric patients
31 May 2016 - Teflaro is the first branded IV antibiotic approved for paediatric patients in more than a decade. ...
Posted by Michael Wonder on 31 May 2016
New cancer immunotherapy indication for Canadian patients with untreated metastatic melanoma
31 May 2016 - New indication marks the third approval for Keytruda in Canada. ...
Posted by Michael Wonder on 31 May 2016
Flixabi, Biogen’s infliximab biosimilar referencing Remicade, approved in the European Union
30 May 2016 - Biogen to manufacture and commercialize Flixabi, the company’s second anti-TNF biosimilar therapy in the EU. ...
Posted by Michael Wonder on 31 May 2016
European Commission approves Imbruvica (ibrutinib) for first-line treatment of patients with chronic lymphocytic leukaemia
31 May 2016 - Imbruvica is now indicated across all lines of chronic lymphocytic leukaemia in the European Union. ...